Research programme: long-acting conjugate therapeutics - Hanmi Pharmaceutical
Alternative Names: HM 11760A; HM 1216OB; HM 12260b; LAPS-FSH; LAPS-IFNβLatest Information Update: 04 Nov 2017
At a glance
- Originator Hanmi Pharmaceutical
- Class Blood coagulation factors; Erythropoietins; Follicle stimulating hormones; Glucagon-like peptides; Granulocyte colony-stimulating factors; Growth hormones; Interferons; Peptides
- Mechanism of Action Blood coagulation factor replacements; Corticotropin-releasing hormone inhibitors; Erythropoiesis stimulants; Factor X stimulants; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Granulocyte colony stimulating factor replacements; Growth hormone-releasing hormone inhibitors; Intercellular signalling peptide and protein stimulants; Interferon alpha stimulants; Interferon beta stimulants; Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acromegaly; Anaemia; Cancer; Growth disorders; Haemophilia; Hepatitis C; Infertility; Multiple sclerosis; Neutropenia; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Growth-disorders in South Korea (Parenteral)